943617-66-1

Basic information

• Product Name: methyl 4-(4-chloro-2-nitrophenoxy)benzoate
• Synonyms: methyl 4-(4-chloro-2-nitrophenoxy)benzoate
• CAS NO: 943617-66-1
• Molecular Weight: 307.69
• Mol File: 943617-66-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 4-(4-chloro-2-nitrophenoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(4-chloro-2-nitrophenoxy)benzoate(943617-66-1)
• EPA Substance Registry System: methyl 4-(4-chloro-2-nitrophenoxy)benzoate(943617-66-1)

Safety Data

• Hazardous Substances Data: 943617-66-1(Hazardous Substances Data)

Upstream product

• 345-18-6 2-fluoro-5-chloronitrobenzene 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 89-61-2 2,5-dichloronitrobenzene 

Downstream Products

• 736162-72-4 4-(4-chloro-2-nitrophenoxy)benzoic acid 
• 943617-69-4 4-(4-chloro-2-nitrophenoxy)-N-(2-methoxyethyl)benzamide 
• 943617-67-2 4-(4-chloro-2-nitrophenoxy)benzoyl chloride 
• 1350765-28-4 4-(4-chloro-2-((4-chloro-3-(trifluoromethyl)phenyl)sulfonamido)phenoxy)benzoic acid 
• 1350765-41-1 methyl 4-(4-chloro-2-((4-chloro-3-(trifluoromethyl)phenyl)sulfonamido)phenoxy)benzoate 
• 1350765-34-2 4-(4-chloro-2-((3,4-dichlorophenyl)sulfonamido)phenoxy)benzoic acid 
• 1350765-47-7 methyl 4-(4-chloro-2-((3,4-dichlorophenyl)sulfonamido)phenoxy)benzoate 
• 941116-96-7 methyl 4-(2-amino-4-chlorophenoxy)benzoate 
• 1350765-11-5 C₂₆H₂₂Cl₂F₅N₃O₄S 
• 1350765-05-7 C₂₆H₂₄Cl₂F₃N₃O₄S 
• 1350765-00-2 C₂₇H₂₆Cl₂F₃N₃O₄S 
• 1350764-99-6 C₂₆H₂₆Cl₃N₃O₄S 

Relevant articles and documents

Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2

Covalently acting inhibitors constitute a large and growing fraction of approved small-molecule therapeutics as well as useful tools for a variety of in vitro and in vivo applications. Here, we aimed to develop a covalent antagonist of CC chemokine recept

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.